Medical technology company Becton, Dickinson and Company (BD) has launched the BD Intraosseous (IO) Vascular Access System in the US.

The BD IO system is designed to enable vascular access and allow quick delivery of fluids and medications in emergencies. It enables medical professionals to insert a needle into the bone marrow cavity when intravenous (IV) access is either difficult or delayed.

The system provides fast access to the circulatory system for both adult and paediatric patients.  

Designed for quick intervention in emergencies, it is said to be the only intraosseous device that can be placed after attaching the extension set.

The BD Intraosseous Vascular Access System also features an integrated passive needle-tip safety mechanism to protect both patients and providers from needlestick injuries.

Clinicians can stabilise the device on any surrounding anatomy and choose from five needle lengths for diverse patient needs to accommodate a broad range of patients.

Unlike other devices, the BD powered driver has a rechargeable battery, lasting up to 12 times longer than non-rechargeable options.

In addition, its multi-light battery indicator shows battery status, ensuring that clinicians are confident that the drill is powered for the procedure.

BD medication delivery solutions worldwide president Eric Borin said: “In emergency situations, mistakes and delays can have devastating consequences.

“This important innovation represents a significant advancement in rapid vascular access and builds on our ongoing commitment to support medical teams in delivering the highest-quality access and improving patient outcomes during lifesaving emergency health situations.”

IO access provides a stable space for safely administering medications and fluids that can also be given through an IV. BD said that this procedure is considered safe, with serious complications occurring in less than 1% of cases.

In critical situations, such as with patients who have low or no palpable blood pressure, IO placement is twice as likely to succeed compared to peripheral IV or central venous catheter placement.

In late 2022, the medical technology company recalled several intraosseous kits, including Intraosseous Needle Set Kits, Manual Driver Kits, and Powered Drivers, due to potential issues that could delay treatment.